Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229528 · ClinicalTrials.gov registry record · Phase 4
Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease
A Phase 4 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT00229528 is a Phase 4 study that has completed, run by University of Oklahoma. The registered enrollment target is 25 participants.
The verdict
NCT00229528, a Phase 4 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
COAT-platelets stands for collagen and thrombin stimulated platelets, which are two things in the body that make platelets stick together. These platelets may be important in the initiation of a heart attack (myocardial infarction). A chemical in the body called serotonin maybe responsible for COAT-platelet production. Paroxetine causes a significant reduction in platelet serotonin and therefore may have value in preventing heart attacks. Therefore, the current study is designed to determine whether paroxetine will decrease COAT-platelet production in normal volunteers and patients with cardiovascular disease.
Interventions
- DRUG Paxil-CR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00229528
The ClinicalTrials.gov registry entry for NCT00229528 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paxil-CR is the first listed.
NCT00229528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00229528 about?
NCT00229528 is a clinical study titled "Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease". COAT-platelets stands for collagen and thrombin stimulated platelets, which are two things in the body that make platelets stick together. These platelets may be important in the initiation of a heart attack (myocardial infarction). A chemical in the body called serotonin maybe responsible for COAT-...
What is the current status of trial NCT00229528?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2004-03. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00229528?
The interventions under investigation include: Paxil-CR (DRUG).
Who is sponsoring clinical trial NCT00229528?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.